-transparent.png){kind=logo}
Twenty-two consecutive patients with newly diagnosed symptomatic, locally advanced or metastatic prostate cancer were treated with intranasal buserelin, a long-acting analogue of gonadotrophin releasing hormone, in divided dosages of between 600 and 1000 micrograms daily. Suppression of testosterone occurred in 1 of 5 patients treated with 600 micrograms daily and in all 17 patients receiving 1000 micrograms daily. Two of 5 patients treated with the 600 micrograms regimen and 16 of 17 patients receiving the 1000 micrograms regimen showed subjective and objective evidence of disease regression. Follow-up was from 1 to 16 months (mean 7.1 months); 6 patients have relapsed during this period. Buserelin offers an effective alternative medical treatment of carcinoma of the prostate and, apart from impotence, does not have the side effects of oestrogens.
J H Waxman, and
J A Wass, and
W F Hendry, and
H N Whitfield, and
P Bary, and
G M Besser, and
J S Malpas, and
R T Oliver
December 1985,
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
J H Waxman, and
J A Wass, and
W F Hendry, and
H N Whitfield, and
P Bary, and
G M Besser, and
J S Malpas, and
R T Oliver
December 1983,
The British journal of dermatology,
J H Waxman, and
J A Wass, and
W F Hendry, and
H N Whitfield, and
P Bary, and
G M Besser, and
J S Malpas, and
R T Oliver
June 1998,
Bailliere's clinical obstetrics and gynaecology,
J H Waxman, and
J A Wass, and
W F Hendry, and
H N Whitfield, and
P Bary, and
G M Besser, and
J S Malpas, and
R T Oliver
January 1994,
Hormone research,
J H Waxman, and
J A Wass, and
W F Hendry, and
H N Whitfield, and
P Bary, and
G M Besser, and
J S Malpas, and
R T Oliver
October 1989,
Australian paediatric journal,
J H Waxman, and
J A Wass, and
W F Hendry, and
H N Whitfield, and
P Bary, and
G M Besser, and
J S Malpas, and
R T Oliver
October 1991,
British journal of obstetrics and gynaecology,
J H Waxman, and
J A Wass, and
W F Hendry, and
H N Whitfield, and
P Bary, and
G M Besser, and
J S Malpas, and
R T Oliver
August 1988,
Seminars in oncology,
J H Waxman, and
J A Wass, and
W F Hendry, and
H N Whitfield, and
P Bary, and
G M Besser, and
J S Malpas, and
R T Oliver
January 1987,
Progress in clinical and biological research,
J H Waxman, and
J A Wass, and
W F Hendry, and
H N Whitfield, and
P Bary, and
G M Besser, and
J S Malpas, and
R T Oliver
May 1982,
Lancet (London, England),
J H Waxman, and
J A Wass, and
W F Hendry, and
H N Whitfield, and
P Bary, and
G M Besser, and
J S Malpas, and
R T Oliver
April 1989,
Cancer,
